Speciality Medi.

Why is Speciality Medicines Ltd falling/rising?

As of 18-Jul, Speciality Medicines Ltd's stock price is rising to Rs 185.50, up 3.86% today and outperforming its sector. However, it has declined 11.20% over the past month, with reduced investor participation and mixed performance against longer-term moving averages.

As of 18-Jul, Speciality Medicines Ltd's stock price is rising, currently at Rs 185.50, reflecting a change of Rs 6.9 or 3.86%. The stock has outperformed its sector by 5.27% today and has been on a consecutive gain for the last two days, accumulating a total return of 4.04% during this period. Additionally, the stock opened with a gain of 3.86% today and reached an intraday high of Rs 185.50.<BR><BR>Despite this positive movement, there are some concerning trends. The stock has experienced a decline of 11.20% over the past month, and there has been a notable decrease in investor participation, with delivery volume falling by 19.35% compared to the 5-day average. Furthermore, while the stock is currently above its 5-day moving average, it remains below the 20-day, 50-day, 100-day, and 200-day moving averages, indicating mixed performance over longer periods.<BR><BR>Overall, the current rise in the stock price can be attributed to recent gains and positive performance relative to the sector, despite underlying challenges in investor participation and longer-term moving averages.

Which are the latest news on Speciality Medi.?

What does Speciality Medi. do?

Speciality Medicines Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 180 Cr. It has no reported sales or profits for the latest quarter, a P/E ratio of 14.00, and a return on equity of 18.30%.

Overview:<BR>Speciality Medicines Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>There are no details available regarding the incorporation year or any status changes. Additionally, no sales or profit data has been reported for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 180 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 14.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.25<BR>Return on Equity: 18.30%<BR>Price-to-Book: 2.65<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Speciality Medi.?

As of 10th June, Speciality Medicines Ltd has a market capitalization of 180.00 Cr, classifying it as a Micro Cap company. There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Speciality Medicines Ltd has a market capitalization of 180.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 30.42 Cr and Total Assets valued at 39.98 Cr.

Who are the peers of the Speciality Medi.?

Peers of Speciality Medi. include Kerala Ayurveda, Aarey Drugs, Nectar Lifesci., Syschem (India), Brooks Lab., Oxygenta Pharma, Coral Labs., and Sanjiv. Parant. Aarey Drugs has the highest 1-year return at 45.51%, while Kerala Ayurveda has the lowest at -64.41%, and management risks vary from below average to good among peers.

Peers: The peers of Speciality Medi. are Kerala Ayurveda, Aarey Drugs, Nectar Lifesci., Syschem (India), Brooks Lab., Oxygenta Pharma, Coral Labs., Sanjiv.Parant.<BR><BR>Quality Snapshot: Below Average management risk is observed at Kerala Ayurveda, Aarey Drugs, Nectar Lifesci., Syschem (India), Brooks Lab., Coral Labs., and Oxygenta Pharma, while Good management risk is found at Sanjiv.Parant. Average growth is noted at Nectar Lifesci., while Good growth is seen at Syschem (India) and Sanjiv.Parant, with the rest showing Below Average growth. Capital Structure is Excellent at Coral Labs., Good at Syschem (India) and Sanjiv.Parant, and Below Average at the remaining peers.<BR><BR>Return Snapshot: Aarey Drugs has the highest 1-year return at 45.51%, while Kerala Ayurveda has the lowest at -64.41%, with Speciality Medi. not having a reported 1-year return. Additionally, Oxygenta Pharma, Brooks Lab., Nectar Lifesci., and Kerala Ayurveda all have negative six-month returns.

When is the next results date for Speciality Medicines Ltd?

The next results date for Speciality Medicines Ltd is 28 May 2026.

The next results date for Speciality Medicines Ltd is scheduled for 28 May 2026.